medmix AG designs, produces, and sells high-precision devices and services in Switzerland and internationally. It operates through the Healthcare, and Consumer and Industrial segments. The company offers dispensers, cartridges, mixers, tips, syringes, pen, and auto injectors for delivery of dental materials; delivery devices and mixing for bone repair and tissue treatment, which are used for prosthetics, restoratives, anesthetics, and aesthetics; the pen and auto injectors, which are used in fertility and growth hormone treatments, treatment of diabetes, osteoporosis, and other diseases; and the delivery and mixing devices, which are used by tissue banks and medical device OEMs. It also produces and markets dispensers, cartridges, and mixers for two-component adhesives and sealants for use in construction, transportation, electronics, infrastructure, and general industrial sectors; and micro-brushes and applicators for eyes, eyelashes, lips, and facial make-up. The company offers its products under the Mixpac, Transcodent, Qiaoyi, Cox, MK, Medmix, Haselmeier, and Geka brands. medmix AG was founded in 1922 and is based in Baar, Switzerland.…
SPI-Wert Medmix-Aktie: So viel Verlust hätte ein Medmix-Investment von vor 3 Jahren eingebracht
medmix (SWX: MEDX) is listed on the SIX Swiss Exchange, where its shares trade in CHF. It belongs to the Specialty Industrial Machinery industry, part of the Industrials sector, and reports about 2,587 employees.
The shares were at 9.580 CHF on 20 November 2026, up 15.3% over 52 weeks. Its 52-week range is 7.610 CHF to 12.36 CHF: the price is 22.5% below the high and 25.9% above the low.
Its market capitalisation is 389.65M CHF. It pays a dividend yielding 1.02%, against a median of 1.67% among the dividend payers in that peer group.
medmix reports return on equity of 1.5%, an operating margin of 6.6% and revenue down 4.9% year over year.
Its debt exceeds its cash by 208.10M CHF, a debt-to-equity ratio of 0.78. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 3 analysts cover the stock; their mean price target of 14.97 CHF is 56.2% above the current price. The next earnings report is expected on 25 February 2027.